Gyre Therapeutics
GYRE
41 hedge funds and large institutions have $21.6M invested in Gyre Therapeutics in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 2 closing their positions.
6,538% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $16K
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
11% more funds holding
Funds holding: 37 → 41 (+4)
7% more capital invested
Capital invested by funds: $20.2M → $21.6M (+$1.43M)
0.36% more ownership
Funds ownership: 1.72% → 2.08% (+0.36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$684K |
| 2 |
State Street
Boston,
Massachusetts
|
+$284K |
| 3 |
BlackRock
New York
|
+$221K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$110K |
| 5 |
Goldman Sachs
New York
|
+$97.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
-$227K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$227K |
| 3 |
Morgan Stanley
New York
|
-$38.2K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.8K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.08K |
GYRE Hedge Fund Activity: Q4 2024 in Review
41 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2024, worth a combined $21.6M — up 7.1% from $20.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GYRE positions and 2 closed out — a net gain of 4 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was UBS Group, adding an estimated $684K. The largest seller was Advantage Alpha Capital Partners, cutting an estimated $227K.
- 41 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2024, up from 37 in Q3 2024.
- Funds reported $21.6M of Gyre Therapeutics stock for Q4 2024, up 7.1% quarter-over-quarter.
- 6 funds opened new Gyre Therapeutics positions in Q4 2024 and 2 closed out, a net change of +4 holders.
- The largest Gyre Therapeutics buyer in Q4 2024 was UBS Group, an estimated $684K added.
- The largest Gyre Therapeutics seller in Q4 2024 was Advantage Alpha Capital Partners, an estimated $227K sold.
Based on aggregated 13F filings for Q4 2024.